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Abstract
Objective: To study the use of hormone therapy (HT), morbidity and reproductive 
outcomes of women with primary ovarian insufficiency (POI) due to FSH-resistant ovaries 
(FSHRO).
Design: A prospective follow-up study in a university-based tertiary clinic setting.
Methods: Twenty-six women with an inactivating A189V FSH receptor mutation were 
investigated by means of a health questionnaire and clinical examination. Twenty-two 
returned the health questionnaire and 14 were clinically examined. Main outcome 
measures in the health questionnaire were reported as HT, morbidity, medication 
and infertility treatment outcomes. In the clinical study, risk factors for cardiovascular 
disease (CVD) and metabolic syndrome (MetS) were compared to age-matched controls 
from a national population survey (FINRISK). Average number of controls was 326 per 
FSHRO subject (range 178–430). Bone mineral density and whole-body composition 
were analyzed with DXA. Psychological and sexual well-being was assessed with Beck 
Depression Inventory (BDI21), Generalized Anxiety Disorder 7 (GAD-7) and Female Sexual 
Function Index (FSFI) questionnaires.
Results: HT was initiated late (median 18 years of age) compared with normal puberty 
and the median time of use was shorter (20–22 years) than the normal fertile period. 
Osteopenia was detected in 9/14 of the FSHRO women despite HT. No major risk factors 
for CVD or diabetes were found.
Conclusions: HT of 20 years seems to be associated with a similar cardiovascular and 
metabolic risk factor profile as in the population control group. However, optimal bone 
health may require an early-onset and longer period of HT, which would better correspond 
to the natural fertile period.
Introduction
Primary ovarian insufficiency (POI) is a clinical condition 
defined by loss of ovarian activity before the age of 40 years 
(1). Characteristic features include menstrual disturbances 
(amenorrhea or oligomenorrhea), elevated levels of FSH 
and low estradiol and anti-Müllerian hormone (AMH) 
levels. The etiology of POI is heterogeneous with a 
significant genetic contribution (2). Ten to fifteen percent 
of POI patients have an affected first-degree relative (3). 
Autosomal, recessively inherited FSH receptor mutations 
underlie a genetic form of POI named FSH-resistant 
ovaries syndrome (FSHRO) (4). The incidence has been 
estimated to be 1:10,000-1:30,000 in Finland. Since 1995, 
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when the mutation was discovered, altogether 40 patients 
have been diagnosed, that is, one affected girl is born every 
year. This inactivating Ala189Val mutation was the first 
genetic form of POI that was functionally characterized in 
detail. The clinical phenotype of FSHRO patients has also 
been carefully analyzed (5). Compared with patients with 
a POI of unknown origin, FSHRO patients were shorter and 
pubertal development was variable but not significantly 
different. Gonadotropin levels were postmenopausally 
high and those of estradiol at the low end of the normal 
range. Levels of AMH were normal in contrast to other 
types of POI (6). Notably, primordial, primary and, in two 
cases, preantral follicles were histologically detected in six 
of the eight FSHRO patients. However, in the absence of 
a functional FSH receptor, follicular maturation did not 
occur, resulting in primary infertility. Infertility in FSHRO 
women has been effectively managed by ovum donation, 
indicating that FSH function is not essential in achieving 
successful pregnancy using donated oocytes (7).
Adverse long-term health outcomes of POI have been 
indicated in several epidemiological and observational 
studies (8, 9, 10, 11). POI is associated with shortened 
life expectancy and increased mortality mainly due to 
CVD, osteoporosis and fractures. In addition, impairment 
of cognitive functions, dementia, Parkinsonism, and 
reduced sexual function and psychological well-being 
have been reported (12). Most of the evidence comes from 
observational studies of women who have undergone 
iatrogenic, surgical menopause in the form of bilateral 
oophorectomy. Long-term health implications of non-
iatrogenic POI may be different due to the more gradual 
and fluctuating course of the disease.
The inactivating FSH receptor mutation was discovered 
20 years ago, but its long-term effects on health and 
morbidity, and the effect of estrogen hormone therapy (HT) 
have not been thoroughly investigated. There is evidence 
that some of the adverse events related to POI may be 
prevented by estrogen HT. Currently, no prospective, 
long-term studies have been carried out to investigate 
the influence of HT in POI. In this study, we assessed the 
health and morbidity of an FSHRO cohort by means of a 
questionnaire, followed by detailed clinical examination.
Materials and methods
Subjects
Altogether 40 FSHRO patients with a confirmed 
inactivating (A189V) FSH receptor (FSHR) mutation have 
been identified in Finland since 1995. We could locate 
26 women, who were sent a questionnaire regarding general 
health, morbidity and fertility. They were also asked to 
participate in an extensive clinical examination. Twenty-
two patients were willing to take part in the clinical study, 
but for practical reasons (moving abroad, ongoing IVF, new-
born infant, another simultaneous health examination, 
transport or timing difficulties) 14 women were clinically 
examined, 12 at Helsinki University Hospital and 2 at Oulu 
University Hospital. All subjects gave written informed 
consent. The study protocol was approved by the Hospital 
District of Helsinki and Uusimaa Ethics Committee for 
Gynecology and Obstetrics, Pediatrics and Psychiatry, and 
the Ethics Committee of Oulu University Hospital.
The control group was formed from participants in 
a national FINRISK 2007 Study. The FINRISK Study is a 
national population risk factor monitoring survey carried 
out at 5-year intervals by the National Institute for Health 
and Welfare (NIHW). For each survey, an independent 
random sample is drawn from the national population 
register stratified by sex and 10-year age group from the 
population aged 25–74 years separately for each survey 
area (13). Altogether, 3013 women were examined in the 
FINRISK 2007 Study and for each FSHRO subject an average 
of 326 (range 178-430) age-matched (±2 years) control 
women were found. The data are collected in the NIHW 
Biobank and we obtained it in the following format: number 
of available control subjects based on the age criteria, mean 
and standard deviation for each parameter. These means 
formed the control group for a given parameter. This study 
was approved by the Ethics Committee of the NIHW.
Questionnaires
The questionnaire included detailed questions regarding 
the use of HT, infertility treatments and their outcome(s), 
bone density measurements and incidence of osteoporosis, 
and cardiovascular symptoms and disease. The patients 
were also asked to report any malignancies, operations, and 
neurological, psychological, respiratory, gastrointestinal, 
cutaneous, or allergy symptoms.
To assess psychological and sexual well-being, the 
following questionnaires were used: Beck Depression 
Inventory (BDI) (14), Generalized Anxiety Disorder 7 
(GAD-7) (15), Female Sexual Function Index (FSFI) (16).
Measurements for lipid profile
For the FSHRO cohort, venous blood samples after 
overnight fasting were collected for the analysis of total 
cholesterol, high-density lipoprotein cholesterol (HDL-c), 
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low-density lipoprotein cholesterol (LDL-c) and 
triglycerides. For the FSHRO group measurements for 
lipids were performed at Helsinki University Hospital 
laboratory (HUSLAB). For the control group assays were 
performed at the Laboratory of Analytical Biochemistry at 
the Center for Health and Welfare.
Oral glucose tolerance test (OGTT)
Oral glucose tolerance tests with 75 g of glucose were 
performed after overnight fasting for 12 h. Venous 
blood samples were drawn to assay levels of glucose and 
insulin at baseline, and at 30, 60 and 120 min in the 
FSHRO cohort and at baseline and 120 min in the control 
group. For the FSHRO group plasma glucose and insulin 
measurements were performed immediately after blood 
sampling at HUSLAB. For the control group assays were 
performed at the Laboratory of Analytical Biochemistry at 
the Center for Health and Welfare. The glucose tolerance 
test results were analyzed according to WHO criteria, 
which defines impaired fasting glucose (IFG) as fasting 
glucose concentrations of 6.1–6.9 mmol/L and impaired 
glucose tolerance (IGT) as 2-h glucose concentrations of 
7.8–11.0 (17). In addition, concentrations of glycosylated 
hemoglobin (HbA1c) were determined in the overnight 
fasting blood samples.
Dual energy X-ray absorptiometry (DXA)
DXA was performed using a Lunar Prodigy Advance 
device (GE Healthcare). Adult whole-body software was 
used for data acquisition and analysis. All patients were 
examined in a supine position. Total body and regional 
body fat and lean masses were assessed. Total body fat 
(TBF), total body lean mass (TBL), android fat (AF), and 
gynoid fat (GF) were expressed as a percentage (%) of 
total body mass. The AF-to-GF ratio (A/G) and TBF-to-TBL 
ratio (TBF/TBL) were calculated. The android region was 
considered to extend from the pubis up to the fifth of an 
ideal line extending from the pubis to the jugulum. The 
gynoid region is considered to be delimited by the upper 
greater trochanters, and a boundary defined at a distance 
of twice the height of the android region. Both AF and GF 
were expressed as percentage of the TBF.
Gynecological examination and 
transvaginal ultrasonography
Standard pelvic examination and transvaginal 
ultrasonography were performed by a trained 
gynecologist (K.L.). Transvaginal ultrasonography was 
performed with GE Voluson E8, D00309 equipment. The 
ovaries were visualized in three dimensions and their 
volumes were calculated. Antral follicle count was performed 
when applicable.
Statistical analysis
When comparing distributions of variables in the FSHRO 
women who completed both the health questionnaire 
study and the clinical examination to the FSHRO women 
who only returned the health questionnaire, the Mann–
Whitney U test was used for continuous variables.
When comparing distributions of variables in the 
FSHRO cohort and the FINRISK control group, conditional 
logistic regression analysis was used. This method was 
selected due to the small number of subjects and the age-
matched control group, where a normal distribution could 
not be assumed. Two-sided P values lower than 0.05 were 
considered statistically significant. Statistical analyses 
were performed using IBM SPSS Statistics 24 software.
Results
Health questionnaire
A cohort of 26 women with a previously confirmed 
inactivating FSH receptor (FSHR) mutation was asked to 
participate in a questionnaire study regarding HT use, 
morbidity and fertility. Twenty-two women (22/26) aged 
28–70 years (median age 51 years) completed and returned 
the questionnaire. The use of HT is summarized in Table 1. 
All patients had been on HT. In addition, three women 
were using local vaginal estrogen therapy at the time of 
the investigation. The median starting age for the use of 
HT was 18 years (range 15–45), and the median time of 
use was 22 years (range 1–35).
Table 1 Use of hormone therapy in the FSHRO cohort as 
reported in the health questionnaire.
Range
HT use (n) 22/22 N.A.
HT current use (n) 10/22 N.A.
Age at HT onset, median 18 15–45
HT use (years), median 22 1–40
HT use below age 50 (years), 
median
19.5 3–33
HT, hormone therapy.
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Reported comorbidities and medications are shown in 
Fig. 1. No coronary heart disease, myocardial infarction 
or other serious cardiovascular events were reported. This 
was lower than expected, as in a national survey self-
reported coronary heart disease or previous myocardial 
infarction in women has ranged from 0.7 to 2.2% (18). 
Reported frequency of statin treatment (2/22; 9.1%) was 
comparable to the national frequency of 12.4% reimbursed 
statin treatments in whole population (National Registry 
for Medication Reimbursement, https://www.kela.fi/
tilastotietokanta-kelasto_sisallysluettelo#Sairastaminen, 
accessed 3.12.2018). The median duration of HT in 
women with hypertension was 28 years versus 20 years in 
women without hypertension. However, the median age 
of women with hypertension (53 years) was also 3 years 
older than women without hypertension.
Eight women (8/22) reported arthritis, and one had 
undergone bilateral total hip arthroplasty as a result of 
arthritis. A majority of the FSHRO women (16/22) had 
undergone bone mineral density assessment (DXA). 
Two women (2/22) reported osteoporosis, seven (7/22) 
had osteopenia, three (3/22) had normal bone mineral 
density, and four (4/22) had either lost their DXA report 
or did not remember the result. There was no significant 
relationship between the duration of HT and osteoporosis 
or osteopenia.
Four women (4/22, 18.2%) were diagnosed with 
asthma, which is slightly more compared to the self-
reported 11.6% in a national health survey of women 
of 30–75 years of age (19). Three (3/22, 13.6%) women 
had suffered from mood disorder and had been treated 
with antidepressants and psychotherapy, which was more 
frequent compared to the reported national prevalence 
of depressive disorders (8.2%) (20). At the time of this 
study, one of FSHRO subjects was using antidepressant 
medication.
Fourteen FSHRO women (14/22) had undergone 
infertility treatments via IVF with donated oocytes, as 
summarized in Supplementary Fig. 1 (see section on 
supplementary data given at the end of this article). 
Altogether 15 live births had been achieved. During 
pregnancy, two women had had pre-eclampsia and one 
had suffered pulmonary embolism. One child, whose 
mother had anti-nuclear SSA autoantibodies (anti-
Sjögren’s-syndrome-related antigen A), had a total AV 
block. Otherwise the children were healthy, and all except 
one were full term. Ten women delivered vaginally, four 
women had had an elective cesarean section and one 
woman had had an emergency cesarean section.
Clinical study
Fourteen FSHRO women took part in the clinical part 
of the study. No statistically significant differences were 
found in the demographic characteristics of the FSHRO 
women who completed both the health questionnaire 
and clinical examination and the FSHRO women who 
only returned the health questionnaire (Supplementary 
Table 1). The demographic data of the clinical study 
cohort, as well as lipid and glucose metabolism profiles, 
were compared with those in a national population risk 
factor monitoring study (FINRISK 2007) (18) shown in 
Table 2. The characteristics of the FSHRO study cohort 
were comparable to those of the age-matched controls. 
One of the FSHRO patients (1/22, 7.1%) had medication 
for elevated blood pressure, whereas 27.4% of the FINRISK 
2007 subjects had either BP over 140/90 mmHg or 
medication. Three of the FSHRO patients were smokers 
(3/22, 21.4%), which is markedly higher incidence 
compared to the control group (13.1%).
In the clinical study cohort, all FSHRO patients 
had been on HT, and six (6/14) were currently on it. 
Corresponding to the results of the questionnaire study, 
the median time of HT use was 20 years, which is shorter 
than the normal fertile period. This was mainly a result 
of delayed diagnosis, problems with renewing the 
prescription at GP (after an initial specialist prescription) 
or lack of motivation to undergo HT. None of the FSHRO 
women reported any typical vasomotor climacteric 
symptoms such as hot flushes or night sweats, which 
could diminish compliance to HT.
In gynecological examination, vaginal atrophy (thin, 
pale and dry appearance) was detected in five patients. 
Figure 1
Comorbidities in the FSHRO cohort as reported in the health 
questionnaire. CVD, cardiovascular disease; PPI, proton-pump inhibitor.
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One patient had spotting and a benign cervical polyp was 
removed. Twelve patients had small streak ovaries. In two 
patients (aged 31 and 36) antral follicles were detected.
Lipid profile
To evaluate the risk of CVD, the lipid profile of the FSHRO 
cohort was examined. The results are shown in Fig. 2 in 
comparison with the control group from the national 
FINRISK 2007 Study. No significant differences in the 
lipid measurements were detected between the FSHRO 
cohort and the age-matched control group (P < 0.05). 
It has been suggested that an LDL-c/ HDL-c ratio is a 
better risk indicator for CVD than individual parameters 
(21). In the FSHRO cohort, the LDL-c/HDL-c ratio was 
1.8 (0.99–5.43). When examining women over 50 years 
of age (n=9), the duration of HT did not alter the 
LDL-c/HDL-c ratio significantly. In addition, there was 
no significant relationship with current HT use and the 
LD-cL/HDL-c ratio in this cohort.
Oral glucose test (OGTT)
According to WHO criteria, no cases of diabetes was 
found in the FSHRO cohort. One person had IFG with a 
plasma glucose level of 6.5 mmol/L. No IGT was detected. 
The mean level of HbA1c, reflecting the 3-month average 
of plasma glucose concentrations, was also normal 
(38.6±1.6 mmol/L) corresponding to 5.6%. The parameters 
related to glucose metabolism are shown in Fig. 3A, B and 
C in comparison with the age-matched control group 
from the FINRISK 2007 Study. The mean level of fasting 
glucose in the FSHRO cohort was 5.5 mmol/L, which was 
statistically significantly lower than the control group 
(5.7 mmol/L, P=0.026). No other significant differences 
were found between the groups.
DXA
DXA with whole-body composition analysis was 
performed. The mean amount of TBF was 39.3 kg (range 
31.7–47.1) and the total body lean mass (TBL) was 64.2 kg 
(range 56.0–72.3) resulting in a TBF/TBL ratio of 0.60 
(range 0.44–1.16). To predict the risk for MetS and CVD, 
the android/GF ratio (A/G ratio) was determined. A ratio 
over 0.8 is considered to be a risk factor. The mean A/G 
ratio was elevated 1.0 (range 0.73–1.16). With regard to 
the duration of HT, there was no significant difference in 
the A/G ratio in subgroups that had been on HT for over 
or under 20 years (P=0.343).
Bone mineral density (BMD) was measured at the 
lumbar spine (L1-4) and femur neck. One woman had a 
T-score of −2.8 in her lumbar spine indicating osteoporosis. 
Table 2 Characteristics of the FSHRO clinical study cohort and the control group from the FINRISK 2007 Study.
FSHRO FINRISKI 2007 control
 Range ±s.d.  Range ±s.d.
n 14 326a 178–430
Age (y), mean 50.2 31–70 ±2 years
Height (m) mean 1.62 1.54–1.73 5.7 1.60 0.06
BMI (kg/m2), mean 26.1 21.2–42.1 5.4 26.7 5.3
WHR, mean 0.8 0.77–0.98 0.07 0.85 0.06
Systolic BP (mmHg), mean 126 106–151 13 126 17
Diastolic BP (mmHg), mean 79 69–90 7 78 10
Smoking (%) 21.4% 13.1%
aFor each FSHRO subject an average of 326 age-matched controls were found (range 178–430 controls). In total, 3013 women were examined in the 
FINRISK 2007 Study.
BMI, body mass index; BP, blood pressure; HT, hormone therapy; WHR, waist-to-hip ratio.
Figure 2
Lipid profile of the FSHRO and control groups. Data points for the control 
group represent the mean of all age-matched controls for each FSHRO 
subject from the FINRISK Study. Box indicates mean, bars indicate ±s.d. 
HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein 
cholesterol; TC, total cholesterol; TG, triglycerides.
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This 37-year-old patient had used (and was still using) HT 
for 20 years, but had also smoked daily for 20 years. Eight 
of the FSHRO subjects (64.3%) had T-scores indicating 
osteopenia (−1.0 to −2.5). Six of the osteopenic women 
were not currently using HT. However, as a result of small 
sample size, we found no significant relationship between 
current HT use and osteopenia. Among the women over 
50 years of age (n=9), seven had osteopenia. Five of these 
women had used HT for over 20 years, and we found no 
significant relationship between the duration of the use 
of HT and osteopenia, again most likely due to the small 
sample size.
Psychological and sexual well-being
Primary amenorrhea has been reported to have adverse 
effects on psychological and sexual well-being. The 
Beck Depression Inventory (BDI) was used to assess the 
incidence and severity of depression. The median score 
was 3.5 (range 0–27) indicating no clinical depression. 
Two patients had elevated scores indicating moderate 
depression. No statistically significant association with HT 
use and BDI score was found. To assess generalized anxiety 
disorder in the study cohort, GAD-7 was utilized. Scores 
over 10 indicate GAD. The median score was 0.5 (range 
0–9) indicating no detectable GAD in the FSHRO cohort. 
Accordingly, no statically significant association with HT 
and GAD-7 score was found. To investigate female sexual 
function in the FSHRO cohort, a multidimensional, self-
reported questionnaire was used (FSFI). This includes 
separate assessment of six different domains of sexual 
function: desire, arousal, lubrication, orgasm, satisfaction 
and pain. Each domain is scored on a scale of 0–5, with 
higher scores indicating better function. One subject 
declined answering the FSFI. The mean FSFI score was 
17.5/36 (range 1.5–32.8). Of the FSHRO subjects, 9/13 
scored under 73% of the maximum score, indicating a 
risk of sexual dysfunction. Moreover, 4/13 women scored 
under 33% of the maximum score indicating a high risk 
of sexual dysfunction. Twelve of the FSHRO women 
were in a long-term relationship (marriage, common law 
marriage, registered partnership). Relationship status did 
not have a significant impact on sexual well-being in this 
cohort. The presence of vaginal atrophy did not affect 
the FSFI score. Only one person with vaginal atrophy had 
an FSFI score indicating a risk of sexual dysfunction. No 
statistically significant association was found with current 
HT use or duration of HT use and total the FSFI score or its 
six separate dimensions.
Discussion
The aim of this study was to elucidate the long-term health, 
morbidity and reproductive outcomes of women with the 
FSHRO syndrome and investigate the effect of HT. FSHRO is 
a recessively inherited single gene disorder causing genetic 
POI. Due to its explicit etiology without confounding 
environmental factors, it can serve as a model disease for 
POI. In the FSHRO cohort, a majority of the women had 
osteopenia and one person had osteoporosis despite HT 
use. However, the initiation of HT was late compared to 
the onset of normal puberty. In addition, the median use 
of HT, 20–22 years, provided a significantly shorter period 
of exposure to estrogen than the normal fertile period. No 
major cardiovascular or metabolic disease risk factors or 
morbidity were detected in the FSHRO cohort compared 
to the age-matched control group.
This study revealed high total body fat weight (TBF) 
and an increased android-to-gynoid (A/G) ratio in the 
FSHRO women, reflecting elevated risks of CVD and MetS. 
However, when compared with the age-matched women 
of the FINRISK 2007 population risk factor monitoring 
survey, no elevated risk for CVDs was found in the FSHRO 
women. This may in part be a result of the small number 
of FSHRO subjects, as women with POI have previously 
Figure 3
Glucose metabolism in FSHRO and control 
groups. (A) Mean glucose levels in OGTT. Gluc 0’, 
fasting glucose; gluc 120’, glucose at 120 min. 
*P = 0.026. (B) Mean insulin levels in OGTT. Insulin 
0’, fasting insulin; insulin 120’, insulin at 120 min. 
(C) Mean levels of glycosylated hemoglobin 
(HbA1c). No statistically significant difference 
between the groups (P = 0.136). Data points for 
the control group represent the mean of all 
age-matched controls for each FSHRO subject 
from the FINRISK Study. Box indicates mean, bar 
indicates ±s.d.gluc 0 gluc 120’
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been reported to have greater risks for coronary heart 
disease (CHD), cardiovascular mortality, and all-cause 
mortality, but no association with stroke (22). Usually this 
is attributed to the shortened length of estrogen exposure, 
but it has also been suggested that spontaneous POI is a 
first step on a causal pathway to multiorgan dysfunction. 
Due to effective lifestyle intervention programs in the past 
35 years, Finland has experienced a remarkable change 
from the world’s highest coronary heart disease incidence 
to an 80% decrease in CHD mortality (13), which may in 
part explain our findings. In addition, risk factors for CVD 
and MetS may increase as the FSHRO cohort ages, and a 
follow-up study will enlighten this.
In the FSHRO cohort, eight patients (64,3%) had 
osteopenia and one person had osteoporosis despite 
HT use. However, the median use of HT, 20–22 years, 
provided a significantly shorter period of exposure to 
estrogen than the normal fertile period, and it seems 
that it is not adequate in preventing bone loss. POI is a 
well-established risk factor for osteopenia, osteoporosis 
and fracture, especially if hypoestrogenism begins before 
peak bone mass has been reached (23, 24, 25). The 
risk of fracture is 1.5- to 3-fold higher in women with 
menopause before the age of 45 years compared with 
women with menopause at normal average of 50–51 
years of age (26, 27). HT has been shown to effectively 
reduce this risk and it should be the first-line treatment 
of osteopenia/osteoporosis in women with POI (28, 29). 
Six of the osteopenic FSHRO women were not currently 
using HT and five of them were over 50 years of age. The 
effect of HT withdrawal on bone loss has been mostly 
studied in postmenopausal women and the results are 
controversial. Most studies indicate that discontinuation 
of HT is followed by accelerated bone loss, but long-term 
use of HT (over 10–15 years) protects women from bone 
loss (30). We were not able to demonstrate a significant 
relationship between current HT use and bone loss in 
the FSHRO cohort. In contrast, FSH has been shown 
have a direct stimulatory effect on osteoclast-mediated 
bone resorption in mice, and a blocking antibody to the 
β-subunit of FSH has been shown to prevent bone loss 
(31). Furthermore, blocking FSH has recently been shown 
to induce thermogenic adipose tissue and reduce body fat 
in wild-type mice (32). Our clinical findings in women 
with defective FSHR function do not support the proposed 
therapeutic potential of FSH-blocking agents in humans. 
However, it remains to be investigated whether this type 
of FSH action in humans is conveyed through a different 
receptor than the FSHR.
Infertility is often the most devastating aspect of POI 
diagnosis. Women with FSHRO have had the chance to 
conceive using modified IVF and donated oocytes since 
the early 1990s. Early results of these treatments have been 
previously reported (7). Our results are in line with these 
and show that IVF with donated oocytes is an effective 
treatment in this patient group despite the severe hormonal 
abnormality. The rate of pregnancy complications did not 
differ from that in other IVF pregnancies (33). Recently, 
in vitro maturation (IVM) was utilized in treating a woman 
with FSHRO (34). However, the etiology in this case 
remains unclear, and the patient did not harbor a mutation 
in FSHR, as all our patients do. Nevertheless, IVM would 
provide an attractive option for FSHRO women, allowing 
them to have biologically related children.
Women with POI have reported significant levels 
of psychological symptoms such as grief, sadness, and 
diminished self-esteem (35). Depression was more 
common in the FSHRO women compared to the national 
prevalence; however, majority of the women had no 
psychological morbidity. A potential explanation could 
be that the FSHRO women were already psychologically 
adjusted to the POI diagnosis at the time of the current 
study, since due to their primary amenorrhea, their 
diagnoses had been made at a younger age compared with 
older POI patients. Additionally, all FSHRO patients have 
had genetic counseling to explain the genetic etiology of 
the POI, which may have enhanced their psychological 
adjustment. However, a majority of the FSHRO women 
were at risk or at high risk of developing sexual dysfunction. 
This is in line with the results of a Brazilian study on 58 
POI patients, where the prevalence of sexual dysfunction 
was 62.1% (36). Similarly, low scores on a sexual function 
scale were reported in young women with spontaneous 
POI who received physiologic estradiol replacement (37). 
Women with POI should be given advice concerning the 
importance of HT and the role of regular sexual activity 
to prevent vaginal atrophy. In addition, sexual counseling 
should be available for this patient group.
In conclusion, our results imply that HT of twenty 
years is sufficient in prevention of major cardiovascular or 
metabolic morbidity. However, optimal bone health and 
bone mineral loss prevention may require early-onset and 
a longer period of HT, mimicking the natural fertile period. 
Women with FSHRO as well as other women with POI should 
be educated about the health effects of hypoestrogenism 
and encouraged to use optimal HT. In addition, sexuality 
and fertility are core issues for women with POI, and these 
should be addressed by health care personnel.
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